HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Foghorn Therapeutics (NASDAQ:FHTX) and maintained a $20 price target.
April 10, 2024 | 10:18 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Foghorn Therapeutics maintains a Buy rating and a $20 price target from HC Wainwright & Co.
The reiteration of a Buy rating and maintenance of a $20 price target by a reputable analyst like Andrew Fein suggests a strong vote of confidence in Foghorn Therapeutics' potential. This positive analyst coverage is likely to influence investor sentiment and could lead to a short-term increase in FHTX's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100